Pancreatic Cancer Screening Using the Enzeavour Assay in Japan (ENZEAVOUR FS)

June 23, 2026 updated by: Cosomil, Inc.

Pancreatic Cancer Screening Using Single-Molecule Enzyme Activity-Based Liquid Biopsy, Enzeavour: A Single-Arm Interventional Feasibility Study Protocol in Japan

This nationwide, multicenter, prospective, single-arm interventional feasibility study evaluates the Enzeavour Pancreatic Cancer assay in routine health checkups and cancer screening in Japan. Approximately 10,000 asymptomatic adults will be enrolled. Participants with an Enzeavour Score above 0.369 will undergo diagnostic work-up as clinically indicated. The primary outcome is pancreatic cancer detection rate within 12 months after the index blood draw, and the secondary outcome is positive predictive value.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Pancreatic cancer is often diagnosed at an advanced stage, and an effective population-based screening strategy has not been established. The Enzeavour Pancreatic Cancer assay is a blood-based test that quantifies the activity of three specific enzymes at a single-molecule level and integrates four biomarkers into a composite Enzeavour Score.

This nationwide, multicenter, prospective, single-arm feasibility study evaluates the Enzeavour assay in routine health checkups and cancer screening in Japan. Approximately 10,000 asymptomatic adults will be enrolled. Participants with an Enzeavour Score greater than 0.369 will be referred for diagnostic work-up as clinically indicated. This study uses a partial verification design with 12-month follow-up for pre-specified subgroups and aims to generate real-world estimates of pancreatic cancer detection rate and positive predictive value for future trial planning.

Study Type

Interventional

Enrollment (Estimated)

10000

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Japan
    • Aichi-ken
      • Nagakute, Aichi-ken, Japan
        • Recruiting
        • Aichi Medical University Hospital
      • Nagoya, Aichi-ken, Japan
        • Recruiting
        • Nagoya University Hospital
    • Hiroshima
      • Hiroshima, Hiroshima, Japan
        • Recruiting
        • Hiroshima University Hospital
      • Onomichi, Hiroshima, Japan
        • Recruiting
        • JA Onomichi General Hospital
        • Contact:
          • Keiji Hanada, MD, Ph.D.
        • Principal Investigator:
          • Keiji Hanada, MD, Ph.D.
    • Hokkaido
      • Obihiro, Hokkaido, Japan
        • Recruiting
        • Obihiro Kosei Hospital
      • Sapporo, Hokkaido, Japan
        • Recruiting
        • Keijinkai Maruyama Clinic
      • Sapporo, Hokkaido, Japan
        • Recruiting
        • Teine Keijinkai Hospital
    • Hyōgo
      • Kobe, Hyōgo, Japan
        • Recruiting
        • Hotel Okura Kobe Clinic
      • Kobe, Hyōgo, Japan
        • Recruiting
        • Kobe University Hospital
    • Ibaraki
      • Mito, Ibaraki, Japan
        • Recruiting
        • Ibaraki Medical Center
      • Mito, Ibaraki, Japan
        • Recruiting
        • Mito Kyodo General Hospital
    • Kagawa-ken
      • Kita-gun Miki-cho, Kagawa-ken, Japan
        • Recruiting
        • Kagawa University Hospital
    • Kanagawa
      • Atsugi, Kanagawa, Japan
        • Recruiting
        • JA Health Management Center Atsugi
      • Isehara, Kanagawa, Japan
        • Recruiting
        • Isehara Kyodo Hospital
      • Kawasaki, Kanagawa, Japan
        • Recruiting
        • St. Marianna University School of Medicine Hospital
      • Sagamihara, Kanagawa, Japan
        • Recruiting
        • Kitasato University Hospital
      • Sagamihara, Kanagawa, Japan
        • Recruiting
        • JA Health Management Center Sagamihara
      • Yokohama, Kanagawa, Japan
        • Recruiting
        • Yokohama City University Medical Center
    • Kochi
      • Kochi, Kochi, Japan
        • Recruiting
        • Clinic Green House
      • Kochi, Kochi, Japan
        • Recruiting
        • Japanese RedCross Society Kochi Red Cross Hospital
      • Kochi, Kochi, Japan
        • Recruiting
        • Kochi Kenshin Clinic
    • Kyoto
      • Kyoto, Kyoto, Japan
        • Recruiting
        • Kyoto University Hospital
      • Kyoto, Kyoto, Japan
        • Recruiting
        • Kyoto Industrial Health Association
    • Mie-ken
      • Matsusaka, Mie-ken, Japan
        • Recruiting
        • Matsusaka Medical Association
      • Tsu, Mie-ken, Japan
        • Recruiting
        • Mie University Hospital
      • Tsu, Mie-ken, Japan
        • Recruiting
        • Mie Healthcare center
    • Oita Prefecture
      • Yufu, Oita Prefecture, Japan
        • Recruiting
        • Oita University Hospital
    • Okinawa
      • Okinawa, Okinawa, Japan
        • Recruiting
        • Nakagami General Chibana Clinic
      • Okinawa, Okinawa, Japan
        • Recruiting
        • Nakagami Hospital
      • Shimajiri-gun Haebaru-cho, Okinawa, Japan
        • Recruiting
        • Okinawa Health Promotion Foundation
    • Osaka
      • Osaka, Osaka, Japan
        • Recruiting
        • NEO Healthcare GI Endoscopy Clinic Honmachi
      • Osaka, Osaka, Japan
        • Recruiting
        • Tane Clinic
      • Osaka, Osaka, Japan
        • Recruiting
        • Tane General Hospital
    • Saitama
      • Saitama, Saitama, Japan
        • Recruiting
        • Jichi Medical University Saitama Medical Center
    • Shiga
      • Ōtsu, Shiga, Japan
        • Recruiting
        • Shiga University of Medical Science Hospital
    • Shizuoka
      • Hamamatsu, Shizuoka, Japan
        • Recruiting
        • Seirei Hamamatsu General Hospital
      • Hamamatsu, Shizuoka, Japan
        • Recruiting
        • Seirei Preventive Health Care Center
    • Tokyo
      • Chuo-ku, Tokyo, Japan
        • Recruiting
        • Medical Check Studio Tokyo Ginza Clinic
      • Itabashi-ku, Tokyo, Japan
        • Recruiting
        • C'est la vie Shinbashi Clinic
      • Itabashi-ku, Tokyo, Japan
        • Recruiting
        • Nihon University Itabashi Hospital
      • Koganei, Tokyo, Japan
        • Recruiting
        • Koganei Tsurukame Clinic
      • Minato-ku, Tokyo, Japan
        • Recruiting
        • The Jikei University Hospital
      • Shinjuku-ku, Tokyo, Japan
        • Recruiting
        • Tokyo Women's Medical University Hospital
      • Shinjuku-ku, Tokyo, Japan
        • Recruiting
        • Miraza Shinjuku Tsurukame Clinic
      • Shinjuku-ku, Tokyo, Japan
        • Recruiting
        • Shinjuku Tsurukame Clinic
    • Wakayama
      • Wakayama, Wakayama, Japan
        • Recruiting
        • Wakayama Medical University Hospital
    • Yamagata
      • Yamagata, Yamagata, Japan
        • Recruiting
        • Yamagata University Hospital
      • Yamagata, Yamagata, Japan
        • Recruiting
        • Public Interest Incorporated Foundation Yamagata Health Promotion Organization

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Asymptomatic adults attending participating facilities for routine health checkups, organized cancer screening, or both
  • Able to understand the study procedures and provide written informed consent before enrollment

Exclusion Criteria:

  • Documented clinical history of pancreatic cancer
  • Considered unable or unwilling to undergo any required diagnostic imaging modality (MRCP, EUS, or contrast-enhanced CT) after a positive index test result
  • Any medical, psychological, or social condition that, in the opinion of the principal investigator at each participating site, makes participation inappropriate or compromises study integrity

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Enzeavour Screening Pathway
Participants undergo peripheral blood collection for the Enzeavour Pancreatic Cancer assay as part of a routine health checkup or organized cancer screening visit. Participants with a positive assay result, defined as an Enzeavour Score greater than 0.369, are referred for diagnostic work-up, including MRCP, EUS, or contrast-enhanced CT, as clinically indicated.
Diagnostic test: Enzeavour Pancreatic Cancer Assay
A blood-based diagnostic assay that quantifies the activity of three specific enzymes at a single-molecule level. Four biomarkers derived from these measurements are integrated into a composite Enzeavour Score using a predefined discriminant function. Participants with a score above the pre-specified cut-off of 0.369 are considered test-positive and referred for diagnostic work-up.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pancreatic Cancer Detection Rate
Time Frame: Within 12 months after the index blood draw
The proportion of all enrolled participants diagnosed with pancreatic cancer within 12 months of the index blood draw. A confirmed case is defined as pancreatic cancer confirmed histopathologically or cytologically, or clinically diagnosed based on multidisciplinary team judgment.
Within 12 months after the index blood draw

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Positive Predictive Value of the Enzeavour Assay
Time Frame: Within 12 months after the index blood draw
The proportion of participants with a positive index test result, defined as an Enzeavour Score greater than 0.369, who are subsequently diagnosed with histopathologically confirmed pancreatic cancer within 12 months after the index blood draw.
Within 12 months after the index blood draw

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Detection Rates of Other Pancreatic Diseases and High-Risk Radiological Findings
Time Frame: Within 12 months after the index blood draw
Descriptive analysis of detection rates for various pancreatic diseases and high-risk radiological findings identified during diagnostic work-up and follow-up.
Within 12 months after the index blood draw
Comparison With Conventional Tumor Markers
Time Frame: Baseline through 12 months
Comparison of positivity rates and detection rates between the Enzeavour assay and conventional tumor markers, including CA19-9, overall and within the Enzeavour-positive subgroup.
Baseline through 12 months
Imaging Correlates of Assay Results
Time Frame: Baseline through 12 months
Comparative analysis of MRCP findings according to assay status and retrospective re-evaluation of baseline imaging in confirmed cancer cases.
Baseline through 12 months
Preliminary Longitudinal Performance Measures
Time Frame: 365 days after the index blood draw
Descriptive estimation of specificity and incidence rates for pancreatic and extra-pancreatic malignancies during follow-up.
365 days after the index blood draw

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cosomil, Inc.

Investigators

  • Principal Investigator: Keiji Hanada, MD, Ph.D., JA Onomichi General Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 4, 2026

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2028

Study Registration Dates

First Submitted

May 11, 2026

First Submitted That Met QC Criteria

May 18, 2026

First Posted (Actual)

May 26, 2026

Study Record Updates

Last Update Posted (Actual)

June 26, 2026

Last Update Submitted That Met QC Criteria

June 23, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • A250007-T (Other Identifier: Kobe University Hospital Interventional Research Ethics Committee)
  • JPNP23019 (Other Grant/Funding Number: The New Energy and Industrial Technology Development Organization (NEDO))
  • UMIN000059647 (Registry Identifier: University hospital Medical Information Network (UMIN) Center)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be made publicly available.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pancreatic Neoplasms

Clinical Trials on Enzeavour Pancreatic Cancer Assay

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe